Safety of Simvastatin in LAM and TSC

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-03-31

Study Completion Date

2019-12-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this research study is to see if simvastatin can be taken safely in patients with either LAM or TSC, who are already being treated with everolimus or sirolimus. This is the first step in looking at simvastatin as a drug that may help patients, by impacting the growth and survival of cells that make up the lung lesions that cause problems in LAM and TSC patients. The study also seeks to learn more about how simvastatin works, when given to patients being treated with everolimus or sirolimus, and to evaluate the safety and any potential benefit to patients taking this 2-drug combination.

The primary objective of this study is to determine the safety of simvastatin in the treatment of LAM-S or LAM-TS in patients on a stable (for at least 3 months) dose of sirolimus or everolimus.

Secondary objectives include:

* To assess the effect of simvastatin on forced expiratory volume in 1 second (FEV1).
* To assess the effect of simvastatin on forced vital capacity (FVC).
* To assess the effect of simvastatin on diffusing lung capacity (DLCO).
* To assess the effect of simvastatin on vascular endothelial growth factor -D (VEGF-D) serum levels.
* To assess the effect of simvastatin with questionnaire- based assessments of dyspnea, fatigue, and quality of life (QOL).
* Assess signs of clinical benefit.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis

NCT02737202

Pulmonary Lymphangioleiomyomatosis

TERMINATED PHASE2

Using Romiplostim to Treat Low Platelet Counts During Chemotherapy in People With Lymphoma

NCT04673266

Lymphoma Patients Thrombocytopenia

ACTIVE_NOT_RECRUITING PHASE2

A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia

NCT06986174

Waldenström Macroglobulinemia Lymphoplasmacytic Lymphoma B-Cell Lymphoproliferative Disorder +1 more

RECRUITING PHASE2

Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

NCT02677948

Chronic Lymphocytic Leukemia Lymphoma, Small Lymphocytic

WITHDRAWN PHASE1/PHASE2

A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome

NCT01513317

Myelodysplastic Syndrome

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

After providing written informed consent, study related tests/procedures will be done to ensure eligibility for the study. If found to be eligible, the participant will be given simvastatin at a starting dose of 20 mg, to be taken each evening by mouth. If after 2 months the simvastatin 20 mg dose is tolerated, the dose of simvastatin will be increased to 40 mg each evening by mouth. Doses may be adjusted as needed, should the participant experience side effects from simvastatin. The participant's dose of everolimus or sirolimus is not expected to change, as this is a dose that has been previously tolerated. If side effects occur as a result of the combination of drugs, the dosages may be adjusted by the study physician (investigator).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lymphangioleiomyomatosis Tuberous Sclerosis Complex

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

simvastatin treatment arm

Eligible patients on sirolimus or everolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.

Group Type EXPERIMENTAL

Simvastatin

Intervention Type DRUG

Eligible patients on sirolimus or everolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.

Sirolimus Oral Product

Intervention Type DRUG

Eligible patients on sirolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.

Everolimus Oral Product

Intervention Type DRUG

Eligible patients on everolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Simvastatin

Eligible patients on sirolimus or everolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.

Intervention Type DRUG

Sirolimus Oral Product

Eligible patients on sirolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.

Intervention Type DRUG

Everolimus Oral Product

Eligible patients on everolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

trade name Zocor Rapamune Afinitor

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female, age 18 and older with clinically definitive diagnosis (biopsy proven or compatible chest CT/MRI scan) of sporadic LAM (LAM-S) or LAM associated with TS (LAM-TS).
* Treated with a stable (at least 3 months) dose of sirolimus or everolimus
* Negative pregnancy test (women of child bearing potential) at screening.
* Women of childbearing potential must be using barrier, medically acceptable contraceptive precautions.
* Signed and dated informed consent.

Exclusion Criteria

* Age \< 18 years
* Known allergy to simvastatin or currently taking simvastatin, or therapy with a medication in the same class as simvastatin within the past 30 days.
* Allergy to sirolimus or everolimus.
* Current use of other than sirolimus or everolimus investigational drug for TSC or LAM within the past 30 days.
* Use of estrogen containing medications, including birth control pills, within the 30 days prior to enrollment.
* Treatment with drugs having known metabolic interactions with statin drugs (e.g. cytochrome P450 3A4 metabolism), including ketoconazole, itraconazole, fluconazole, erythromycin, clarithromycin, azithromycin, niacin (nicotinic acid), digoxin, warfarin, sildenafil or use of strong CYP3A4 inhibitors including gemfibrozil, cyclosporine, danazol, verapamil, diltiazem, and dronedarone. amiodarone, amlodipine, and ranolazine.
* Participation in another clinical study(ies) of an investigational treatment or drug within 30 days prior to the screening visit.
* Amiodarone; within the past 30 days.
* Significant dysfunction of liver (ALT \> 2 times upper limit of normal-ULN), kidney (serum creatinine \> 1.5 times ULN), or blood (leucopenia (ANC\<2000), anemia, Hgb \< 11 gm/dl).
* History of inflammatory muscle disease or myopathy.
* Bleeding diathesis or anticoagulant therapy.
* Uncontrolled hyperlipidemia or diabetes.
* Pregnant, breast feeding, or plan to become pregnant within the next 6 months
* Inadequate contraception (must agree to barrier method)
* History of organ transplant.
* Active on transplant list.
* Severe or uncontrolled medical conditions which would cause an unacceptable safety risk or compromise compliance with the protocol.
* Unstable seizures (recent changes in pattern or anti-epileptics).
* Mental illness or cognitive deficit precluding informed consent..
* Inability to attend scheduled clinic visits or comply with study procedures.

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No